Hypertension Signs and Symptoms

Signs and Symptoms

Introduction

Hypertension is the medical term for high blood pressure
Symptoms may come from secondary causes, concomitant diseases, or from target organ damage (TOD)
Assessment with lab tests and imaging may be done to exclude secondary causes, additional cardiovascular risk factors, or TOD

Empagliflozin’s clinical endorsement: Revolutionising guidelines across specialties

08 Jun 2020

In this third issue we take a look at how empagliflozin made a bold impact on clinical guidelines across multiple specialties. We will explore how existing treatment recommendations were altered, and summarise the current guidelines and future perspectives of empagliflozin’s use.

Nebivolol associated with reduced CV risk in hypertension and CHF

Prof. Michael Weber, Prof. Giuseppe Mancia, Dr. Nelson Abelardo, 08 Nov 2016

The use of beta-blockers in patients with cardiovascular (CV) disorders is somewhat controversial. However, many of the problems associated with traditional first- and second-generation beta-blockers may not be applicable to third-generation beta-blockers. Professor Michael Weber from the State University of New York, US, Professor Giuseppe Mancia from the University of Milano-Bicocca, Italy, and Dr Nelson Abelardo from the University of the Philippines, discussed the role of beta-blockers in managing patients with hypertension and chronic heart failure (CHF) at a recent Menarini-sponsored symposium held during the International Society of Hypertension 2016 meeting in Seoul, Korea, highlighting the potential benefits associated with newer beta-blockers such as nebivolol (Nebilet^®, Menarini).

ACE inhibitor-based combination therapy important for improving BP control in the Asia Pacific region

Prof. Abdul Rashid, Prof. Martin Strauss, Prof. Alistair Hall, 12 Dec 2016

Hypertension is a leading cause of mortality globally and is of particular concern in the Asia Pacific region where there are more deaths due to poor blood pressure (BP) control than in any other region in the world. At a recent Servier-sponsored satellite symposium held during the ASEAN Federation of Cardiology Congress in Yangon, Myanmar, Professor Abdul Rashid, An Nur Specialist Hospital, Selangor, Malaysia, discussed the challenges associated with managing hypertension in the region. In addition, Professor Martin Strauss, North York General Hospital, Toronto, Canada and Professor Alistair Hall, Leeds General Infirmary, UK, discussed the different effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) outcomes, highlighting the additional protection against myocardial infarction (MI) offered by ACE inhibitors such as perindopril.